Windward Bio opened at $18.35 on Nasdaq, 8% above the $17 price of its IPO.
The Basel biotech raised about $175 million, with Sanofi taking another $50 million in a private placement alongside it. It is developing long-acting treatments for asthma, COPD and atopic dermatitis.
顯示更多